Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 304-149-5 | CAS number: 94246-75-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Under the given test conditions the animals exposed to the test substance, Reactive Blue 234, does not elicit sensitising response in LLNA assay. Negative results in cell proliferation revealed that the test substance Reactive Blue 234 could not be a contact allergen in mice. The test substance provides negative sensitising response in LLNA assay.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 05.08. – 18. 08. 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- Council Regulation (EC) No.640/2012, published in O.J. L 193, 2012
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- Balb/c
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Breeding farm VELAZ s.r.o., Unětice 139, 252 62, Czech Republic, RČH CZ 21760118
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 8 to 10 weeks
- Weight at study initiation: 18.75 – 20.93 g
- Housing: macrolon cages with sterilized softwood shavings, monitored conditions, microbiologically defined background, according to internal SOP No.40
Cleaning and disinfection of animal room was regularly performed, as it is described in internal SOP No.10.
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: 21 days
- Indication of any skin lesions: no clinical changes, all animals were examined during the acclimatisation period
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C, permanently monitored
- Humidity (%): 30 – 70 %, permanently monitored
- Photoperiod (hrs dark / hrs light): 12 hours light/dark cycle: 6am-6pm/6pm-6am
- Air changes (per hr): not specified
IN-LIFE DATES:
from: 15. 07. 2015 (acclimatization)
to: 17. 08. 2015 (necropsy) - Vehicle:
- other: DAE 433 (mixture of 40% dimethylacetamide, 30% acetone and 30% ethanol)
- Concentration:
- The test substance was administered in the form of suspension in DAE 433.
Concentrations of test substance in application form:
75% (w/v) 750 mg/mL
7.5% (w/v) 75 mg /mL
0.75% (w/v) 7.5 mg /mL - No. of animals per dose:
- Exposed groups – 15 females (5 animals in three groups)
Positive control group – 5 females
Negative control group – 5 females - Details on study design:
- PRE-SCREEN TESTS:
- Compound solubility:
The appropriate suspensions of the test substance (75%, 7.5%, 0.75% w/v) was applied to three animals in volume 25 ul to the dorsum of each ear once a day morning for 3 consecutive days. The suspensions were prepared before the start of application by mixing on magnetic stirrer and then were still mixed during application. The application was performed very slowly by micropipette. The route of administration was the same as in the main study.
- Irritation: no erythema and skin reaction
- Systemic toxicity: no clinical symptoms of systemic toxicity
- Ear thickness measurements: without any changes, during the pathological examination the auricular lymph nodes enlargement was not detected
- Erythema scores: no erythema and skin reaction
MAIN STUDY
Note: No symptoms of toxicity and no erythema on application site were observed in all animals from the negative control group and all animals administered by the test substance.
ANIMAL ASSIGNMENT AND TREATMENT
Animals were subjected to a clinical examination (health check) shortly after arrival. No clinical changes were recorded.
After acclimatization the animals have been randomly allocated to the dose groups (acc. to internal SOP No.42) and assigned animal numbers.
- Criteria used to consider a positive response:
Cell proliferation
Positive response: the stimulation index (SI) is ≥ 3, and the response increases in dose-related manner
Negative response: the stimulation index (SI) is < 3 without the dose – response relationship
Ambiguous response: the stimulation index is < 3, but the response increases in dose-related manner (dose–response relationship), and eventually statistical significance is observed.
Ear weight – irritation effect
If a statistically significant increase of ear weight together with clear concentration dependence of the effect is recorded, the inflammatory effect is considered as irritation induced by the test substance.
Positive result in cell proliferation reveals that the test substance could be a contact allergen. When positive irritation effect in animals is demonstrated simultaneously, the possibility can not be ruled out that the evaluation based on cell proliferation could be a false positive.
TREATMENT PREPARATION AND ADMINISTRATION:
the same as in the pre-screen test (see above) - Positive control substance(s):
- other: Dinitrochlorobenzene (DNCB)
- Statistics:
- For statistical calculations the software Statgraphic ® Centurion (version XV, USA) was used. Statistical evaluation of measured parameters was performed at first by applying the non-parametric Kruskal-Wallis test for testing whether all group samples originate from the same distribution and then the non-parametric two-group Mann-Whitney rank test (probability level 0.05) for two-group comparisons.
- Positive control results:
- All animals in the positive control group showed symptoms caused by the application of DNCB: hyperaemia of skin with well defined erythema on application site, clonospasm and increased response to stimuli.
- Key result
- Parameter:
- SI
- Value:
- < 3
- Test group / Remarks:
- 1. (5 animals), 75% (w/v), 750 mg/mL
- Key result
- Parameter:
- SI
- Value:
- < 3
- Test group / Remarks:
- 2. (5 animals), 7.5% (w/v), 75 mg /mL
- Key result
- Parameter:
- SI
- Value:
- < 3
- Test group / Remarks:
- 3. (5 animals), 0.75% (w/v), 7.5 mg /mL
- Cellular proliferation data / Observations:
- CELLULAR PROLIFERATION DATA
The value of DPM and SI for positive control group was increased. The SI was ≥ 3 (9.91) – the LLNA was efficient.
The SI for the test groups treated with the test substance at all dose level is below the threshold, and stimulation index (SI) is < 3.
The value of DPM at all dose levels was not statistically significantly increased compared to negative control. On the contrary statistically significant decrease of DPM value at the lowest dose level was observed.
DETAILS ON STIMULATION INDEX CALCULATION
Stimulation index (for incorporation of 3H-methyl thymidine) was calculated by dividing mean values from exposed groups and the positive control group by the corresponding mean value of the vehicle control group. The index for the vehicle control group was set at 1 by definition.
CLINICAL OBSERVATIONS:
No symptoms of toxicity and no erythema on application site were observed in all animals from the negative control group and all animals administered by the test substance.
All animals in the positive control group showed symptoms caused by the application of DNCB: hyperaemia of skin with well defined erythema on application site, clonospasm and increased response to stimuli.
BODY WEIGHTS
Slight reduction of body weight (in hundredth of grams) was recorded in one animal at the highest dose level.
Body weight increment was calculated from values of day 6 just before necropsy and day 1 before first application. Body weight increment was highest at the lowest dose level. However, the weight fluctuations are common in mice. - Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the given test conditions the animals exposed to the test substance, Reactive Blue 234, does not elicit sensitising response in LLNA assay. Negative results in cell proliferation revealed that the test substance Reactive Blue 234 could not be a contact allergen in mice.
The test substance Reactive Blue 234 provides negative sensitising response in LLNA assay. - Executive summary:
The test substance, Reactive Blue 234, was tested for the assessment of skin sensitisation potential with the murine local lymph node assay. This study is a part of the test substance health hazard evaluation.
The Local Lymph Node Assay (LLNA) with the incorporation of 3H-methyl thymidine radionuclide was used. The testing was conducted according to the Method B.42 – Skin Sensitisation: Local Lymph Node Assay, Council Regulation (EC) No.640/2012, published in O.J. L 193, 2012.
In this study the contact allergenic potential of Reactive Blue 234 was evaluated after topical application to female BALB/c mice. Mice were exposed to three concentrations of test substance suspended in vehicle DAE 433 (mixture of 40% dimethylacetamide, 30% acetone and 30% ethanol) for 3 consecutive days.
In pilot experiment the following concentrations of test substance in application forms were used: 75 %, 7.5 %, 0.75 % (w/v). According to the results of pilot experiment the same doses were confirmed for main study.
Primary proliferation of lymphocytes in the lymph node draining the site of application was evaluated using radioactive labelling of proliferating cells. The ratio of the proliferation in treated groups to that in vehicular controls, termed the Stimulation Index, was determined. The evaluation of ear weight was performed for elimination of false positive findings with certain skin irritants.
Comparison of Stimulation Indexes between treated groups and control vehicle group revealed that the test substance Reactive Blue 234 did not cause a significant increase in radioisotope incorporation into the DNA of dividing lymphocytes of animals treated by the test substance at all concentrations. The Stimulation Index of the treated groups is < 3 and the value of disintegrations per minute (DPM) is not significantly increased compared to negative control.
The test substance did not cause increase of ear weight or other indication of irritation to skin at all dose levels nevertheless statistical significance was observed at the highest and the lowest dose levels.
With regard to the Confidential Test Substance Data Sheet from Sponsor and no dose-response relationship was not possible that irritation of skin was caused. Residues of the test substance on the ears were visible during whole study so it could cause this weight increase.
The animals exposed to the test substance at all doses showed no pathological and no other negative clinical symptoms of intoxication throughout the experiment.
The positive control item Dinitrochlorobenzene (DNCB) as a contact allergen (concentration 0.5% (w/v) elicited the expected reaction pattern with significant increase in Stimulation Index of cell proliferation and of ear weight. Appropriate performance of the assay in the test laboratory was then demonstrated.
Under the given test conditions, the test substance, Reactive Blue 234, provides negative sensitising response in LLNA assay. The SI at all dose levels was < 3.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.